Table 1 Changes observed in patients with nodulosis, arthropathy and osteolysis during pamidronate treatment.
| Before | After | p Value | |
|---|---|---|---|
| Urinary NTX | 550.57 (367) | 252 (204) | 0.01 |
| Alkaline phosphatase | 255.7 (163.1) | 134.9 (36.6) | 0.094 |
| z Score lumbar BMD | −3.25 (1.35) | −1.08 (1.23) | 0.03 |
| z Score whole body BMD | −1.72 (1.57) | −1.18 (1.08) | 0.08 |
| VAS | 1.3 (0.27) | 0.77 (0.62) | 0.06 |
| CHAQ | 1.73 (1.0) | 1.29 (0.76) | 0.094 |
BMD, bone mineral density; CHAQ, Childhood Health Assessment Questionnaire; NTX, cross‐linked N‐telopeptide type I collagen;
VAS, Visual Analogue Scale.
Values are mean (SD).